Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 193

1.

Hepatitis C virus infection: a challenge in the complex management of two cases of multidrug-resistant tuberculosis.

Musso M, Mosti S, Gualano G, Mencarini P, Urso R, Ghirga P, Rianda A, Del Nonno F, Goletti D, Palmieri F.

BMC Infect Dis. 2019 Oct 22;19(1):882. doi: 10.1186/s12879-019-4494-1.

2.

Global tuberculosis prevention: should we start from the beginning?

Sotgiu G, Goletti D, Matteelli A.

Eur Respir J. 2019 Sep 12;54(3). pii: 1901394. doi: 10.1183/13993003.01394-2019. Print 2019 Sep. No abstract available.

PMID:
31515266
3.

QuantiFERON TB Gold Plus for the diagnosis of tuberculosis: a systematic review and meta-analysis.

Sotgiu G, Saderi L, Petruccioli E, Aliberti S, Piana A, Petrone L, Goletti D.

J Infect. 2019 Nov;79(5):444-453. doi: 10.1016/j.jinf.2019.08.018. Epub 2019 Aug 29.

PMID:
31473271
4.

Optimization of the autophagy measurement in a human cell line and primary cells by flow cytometry.

Alonzi T, Petruccioli E, Vanini V, Fimia GM, Goletti D.

Eur J Histochem. 2019 Jun 26;63(2). doi: 10.4081/ejh.2019.3044.

5.

IP-10 contributes to the inhibition of mycobacterial growth in an ex vivo whole blood assay.

Palucci I, Battah B, Salustri A, De Maio F, Petrone L, Ciccosanti F, Sali M, Bondet V, Duffy D, Fimia GM, Goletti D, Delogu G.

Int J Med Microbiol. 2019 Jul;309(5):299-306. doi: 10.1016/j.ijmm.2019.05.005. Epub 2019 May 22.

PMID:
31147175
6.

Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practice.

Cantini F, Niccoli L, Capone A, Petrone L, Goletti D.

Expert Opin Drug Saf. 2019 May;18(5):415-425. doi: 10.1080/14740338.2019.1612872. Epub 2019 May 8. Review.

PMID:
31066297
7.

Characterization of QuantiFERON-TB-Plus results in latent tuberculosis infected patients with or without immune-mediated inflammatory diseases.

Chiacchio T, Petruccioli E, Vanini V, Cuzzi G, Massafra U, Baldi G, Navarra A, Scrivo R, Mastroianni C, Sauzullo I, Esposito C, Palmieri F, Cantini F, Goletti D.

J Infect. 2019 Jul;79(1):15-23. doi: 10.1016/j.jinf.2019.04.010. Epub 2019 Apr 11.

PMID:
30981891
8.

Putting in harm to cure: Drug related adverse events do not affect outcome of patients receiving treatment for multidrug-resistant Tuberculosis. Experience from a tertiary hospital in Italy.

Gualano G, Mencarini P, Musso M, Mosti S, Santangelo L, Murachelli S, Cannas A, Di Caro A, Navarra A, Goletti D, Girardi E, Palmieri F.

PLoS One. 2019 Feb 28;14(2):e0212948. doi: 10.1371/journal.pone.0212948. eCollection 2019.

9.

Severe chest allodynia as an unusual first presentation of hydatid disease: a case report.

Coluzzi F, Meniconi RL, Caruso D, Rivosecchi F, Petrone L, Goletti D, Ettorre GM.

BMC Infect Dis. 2019 Jan 9;19(1):37. doi: 10.1186/s12879-019-3670-7.

10.

Personalization of biologic therapy in patients with rheumatoid arthritis: less frequently accounted choice-driving variables.

Niccoli L, Nannini C, Blandizzi C, Mantarro S, Mosca M, Di Munno O, Goletti D, Benucci M, Gobbi FL, CassarĂ  E, Kaloudi O, Cantini F.

Ther Clin Risk Manag. 2018 Oct 24;14:2097-2111. doi: 10.2147/TCRM.S175772. eCollection 2018.

11.

Complement Component C1q as Serum Biomarker to Detect Active Tuberculosis.

Lubbers R, Sutherland JS, Goletti D, de Paus RA, van Moorsel CHM, Veltkamp M, Vestjens SMT, Bos WJW, Petrone L, Del Nonno F, Bajema IM, Dijkman K, Verreck FAW, Walzl G, Gelderman KA, Groeneveld GH, Geluk A, Ottenhoff THM, Joosten SA, Trouw LA.

Front Immunol. 2018 Oct 23;9:2427. doi: 10.3389/fimmu.2018.02427. eCollection 2018.

12.

The Mycobacterial HBHA Protein: A Promising Biomarker for Tuberculosis.

De Maio F, Squeglia F, Goletti D, Delogu G.

Curr Med Chem. 2019;26(11):2051-2060. doi: 10.2174/0929867325666181029165805. Review.

PMID:
30378481
13.

Can we predict tuberculosis cure? What tools are available?

Goletti D, Lindestam Arlehamn CS, Scriba TJ, Anthony R, Cirillo DM, Alonzi T, Denkinger CM, Cobelens F.

Eur Respir J. 2018 Nov 8;52(5). pii: 1801089. doi: 10.1183/13993003.01089-2018. Print 2018 Nov. Review.

14.

Effect of therapy on Quantiferon-Plus response in patients with active and latent tuberculosis infection.

Petruccioli E, Chiacchio T, Vanini V, Cuzzi G, Codecasa LR, Ferrarese M, SchininĂ  V, Palmieri F, Ippolito G, Goletti D.

Sci Rep. 2018 Oct 23;8(1):15626. doi: 10.1038/s41598-018-33825-w.

15.

Combined use of Quantiferon and HBHA-based IGRA supports tuberculosis diagnosis and therapy management in children.

Sali M, Buonsenso D, D'Alfonso P, De Maio F, Ceccarelli M, Battah B, Palucci I, Chiacchio T, Goletti D, Sanguinetti M, Valentini P, Delogu G.

J Infect. 2018 Dec;77(6):526-533. doi: 10.1016/j.jinf.2018.09.011. Epub 2018 Sep 26.

PMID:
30267797
16.

First description of agonist and antagonist IP-10 in urine of patients with active TB.

Petrone L, Bondet V, Vanini V, Cuzzi G, Palmieri F, Palucci I, Delogu G, Ciccosanti F, Fimia GM, Blauenfeldt T, Ruhwald M, Duffy D, Goletti D.

Int J Infect Dis. 2019 Jan;78:15-21. doi: 10.1016/j.ijid.2018.09.001. Epub 2018 Sep 7.

17.

PE_PGRS3 of Mycobacterium tuberculosis is specifically expressed at low phosphate concentration, and its arginine-rich C-terminal domain mediates adhesion and persistence in host tissues when expressed in Mycobacterium smegmatis.

De Maio F, Battah B, Palmieri V, Petrone L, Corrente F, Salustri A, Palucci I, Bellesi S, Papi M, Rubino S, Sali M, Goletti D, Sanguinetti M, Manganelli R, De Spirito M, Delogu G.

Cell Microbiol. 2018 Dec;20(12):e12952. doi: 10.1111/cmi.12952. Epub 2018 Sep 26.

PMID:
30192424
18.

An evaluation framework for new tests that predict progression from tuberculosis infection to clinical disease.

Kik SV, Schumacher S, Cirillo DM, Churchyard G, Boehme C, Goletti D, Rangaka MX, Denkinger CM, Lienhardt C, Gilpin C, Matteelli A, Cobelens F.

Eur Respir J. 2018 Oct 25;52(4). pii: 1800946. doi: 10.1183/13993003.00946-2018. Print 2018 Oct.

PMID:
30139776
19.

Acute phase proteins and IP-10 as triage tests for the diagnosis of tuberculosis: systematic review and meta-analysis.

Santos VS, Goletti D, Kontogianni K, Adams ER, Molina-Moya B, Dominguez J, Crudu V, Martins-Filho PRS, Ruhwald M, Lawson L, Bimba JS, Garcia-Basteiro AL, Petrone L, Kabeer BS, Reither K, Cuevas LE.

Clin Microbiol Infect. 2019 Feb;25(2):169-177. doi: 10.1016/j.cmi.2018.07.017. Epub 2018 Aug 2.

20.

Evaluation of IP-10 in Quantiferon-Plus as biomarker for the diagnosis of latent tuberculosis infection.

Petrone L, Vanini V, Chiacchio T, Petruccioli E, Cuzzi G, SchininĂ  V, Palmieri F, Ippolito G, Goletti D.

Tuberculosis (Edinb). 2018 Jul;111:147-153. doi: 10.1016/j.tube.2018.06.005. Epub 2018 Jun 12.

Supplemental Content

Loading ...
Support Center